$7.00
00.00%
Last update: Jul 18, 4:00 PM
15 minutes delayed
Comments
Loading...
Oncternal Therapeutics
ONCTNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Oncternal Therapeutics (NASDAQ:ONCT) Stock, Analyst Ratings, Price Targets, Forecasts
Oncternal Therapeutics Inc has a consensus price target of $6.83 based on the ratings of 6 analysts. The high is $19 issued by HC Wainwright & Co. on July 16, 2024. The low is $1.3 issued by Cantor Fitzgerald on September 7, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on July 16, 2024, May 31, 2024, and May 13, 2024, respectively. With an average price target of $19 between HC Wainwright & Co., there's an implied 171.43% upside for Oncternal Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Brookline Capital
Cantor Fitzgerald
BTIG
1calculated from analyst ratings
Analyst Ratings for Oncternal Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/16/2024 | Buy Now | 171.43% | HC Wainwright & Co. | Raghuram Selvaraju | $19 → $19 | Reiterates | Buy → Buy | Get Alert |
| 05/31/2024 | Buy Now | 171.43% | HC Wainwright & Co. | Raghuram Selvaraju | $19 → $19 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | 171.43% | HC Wainwright & Co. | Raghuram Selvaraju | $28 → $19 | Maintains | Buy | Get Alert |
| 04/15/2024 | Buy Now | 300% | HC Wainwright & Co. | Raghuram Selvaraju | $30 → $28 | Maintains | Buy | Get Alert |
| 01/29/2024 | Buy Now | 328.57% | HC Wainwright & Co. | Raghuram Selvaraju | $2 → $30 | Maintains | Buy | Get Alert |
| 12/27/2023 | Buy Now | -71.43% | HC Wainwright & Co. | Raghuram Selvaraju | → $40 | Reiterates | Buy → Buy | Get Alert |
| 12/04/2023 | Buy Now | -71.43% | Brookline Capital | Kemp Dolliver | → $40 | Upgrade | Hold → Buy | Get Alert |
| 09/18/2023 | Buy Now | -71.43% | HC Wainwright & Co. | Raghuram Selvaraju | → $40 | Upgrade | Neutral → Buy | Get Alert |
| 09/07/2023 | Buy Now | -81.43% | Cantor Fitzgerald | Li Watsek | → $26 | Reiterates | Neutral → Neutral | Get Alert |
| 06/06/2023 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju | — | Reiterates | → Neutral | Get Alert |
| 04/04/2023 | Buy Now | — | Maxim Group | Naureen Quibria | — | Downgrade | Buy → Hold | Get Alert |
| 04/04/2023 | Buy Now | — | Brookline Capital | Kemp Dolliver | — | Downgrade | Buy → Hold | Get Alert |
| 04/04/2023 | Buy Now | -81.43% | Cantor Fitzgerald | Li Watsek | $80 → $26 | Maintains | Overweight | Get Alert |
| 04/04/2023 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju | — | Downgrade | Buy → Neutral | Get Alert |
| 04/04/2023 | Buy Now | — | Oppenheimer | Hartaj Singh | — | Downgrade | Outperform → Perform | Get Alert |
| 03/22/2023 | Buy Now | 28.57% | Oppenheimer | Hartaj Singh | $280 → $180 | Maintains | Outperform | Get Alert |
| 03/14/2023 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju | → $140 | Reiterates | → Buy | Get Alert |
| 12/22/2022 | Buy Now | -42.86% | Cantor Fitzgerald | Li Watsek | → $80 | Initiates | → Overweight | Get Alert |
| 08/10/2022 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju | $160 → $140 | Maintains | Buy | Get Alert |
| 05/10/2022 | Buy Now | -50% | Maxim Group | Naureen Quibria | → $70 | Initiates | → Buy | Get Alert |
| 02/24/2022 | Buy Now | -28.57% | BTIG | Kaveri Pohlman | → $100 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Oncternal Therapeutics (ONCT) stock?
The latest price target for Oncternal Therapeutics (NASDAQ:ONCT) was reported by HC Wainwright & Co. on July 16, 2024. The analyst firm set a price target for $19.00 expecting ONCT to rise to within 12 months (a possible 171.43% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Oncternal Therapeutics (ONCT)?
The latest analyst rating for Oncternal Therapeutics (NASDAQ:ONCT) was provided by HC Wainwright & Co., and Oncternal Therapeutics reiterated their buy rating.
When was the last upgrade for Oncternal Therapeutics (ONCT)?
The last upgrade for Oncternal Therapeutics Inc happened on December 4, 2023 when Brookline Capital raised their price target to $2. Brookline Capital previously had a hold for Oncternal Therapeutics Inc.
When was the last downgrade for Oncternal Therapeutics (ONCT)?
The last downgrade for Oncternal Therapeutics Inc happened on April 4, 2023 when Maxim Group changed their price target from N/A to N/A for Oncternal Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Oncternal Therapeutics (ONCT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oncternal Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oncternal Therapeutics was filed on July 16, 2024 so you should expect the next rating to be made available sometime around July 16, 2025.
Is the Analyst Rating Oncternal Therapeutics (ONCT) correct?
While ratings are subjective and will change, the latest Oncternal Therapeutics (ONCT) rating was a reiterated with a price target of $19.00 to $19.00. The current price Oncternal Therapeutics (ONCT) is trading at is $7.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.